GlassScriptPhysician profile
Myra D Downing-Sherman
NPI 1497797344
$8,194.75
in general payments reported to CMS, 2019-2025
37 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,512 · 2022: $2,163 · 2023: $1,790 · 2024: $1,005 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,426 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,425.97 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,659.27 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,074.25 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $641.87 | 2021-2024 | |
| Lilly USA, LLC | $637.04 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $532.60 | 2021-2022 | |
| Astellas Pharma US INC | $505.23 | 2021-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.53 | 2021-2025 | Jardiance |
| Pfizer INC. | $310.98 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $296.49 | 2023-2025 | Voquezna |
| Amgen INC. | $273.48 | 2021-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $227.14 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $199.60 | 2022-2025 | |
| Glaxosmithkline, LLC. | $192.56 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $157.10 | 2023-2025 | Rexulti |
| Medtronic, INC. | $153.02 | 2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myra Downing-Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.